Substances_opioids

Opioid Addiction in New Jersey: Treatment, Withdrawal, and Recovery

By NJ Addiction Centers Editorial Team | Last reviewed: March 27, 2026 | 17 min read Clinically Reviewed

Opioid Addiction in New Jersey: Treatment, Withdrawal, and Recovery

Opioid addiction — clinically termed opioid use disorder (OUD) — is the most lethal substance use crisis in New Jersey’s history. The state recorded over 3,000 suspected opioid-related overdose deaths in 2023, according to the New Jersey Department of Health’s overdose dashboard, with fentanyl present in the majority of cases. Opioid use disorder affects the brain’s reward and pain pathways, creating a pattern of compulsive use despite harmful consequences. Effective treatments exist — including medications such as buprenorphine (Suboxone), methadone, and naltrexone (Vivitrol) — and they are supported by decades of clinical evidence. This guide covers the scope of the opioid crisis in New Jersey, what withdrawal looks like, how treatment works, and where to find NJ-specific resources.

Key Takeaways

Opioid use disorder is a chronic medical condition characterized by compulsive opioid use despite negative consequences, driven by changes in brain chemistry and neural pathways.
Fentanyl has become the dominant driver of overdose deaths in New Jersey, present in approximately 77 percent of fatal overdoses in 2023, according to the NJ Department of Health.
Medication-assisted treatment (MAT) with buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) is the gold-standard treatment for opioid addiction, supported by NIDA, SAMHSA, and the World Health Organization.
Opioid withdrawal is intensely uncomfortable but rarely life-threatening when medically supervised — unlike alcohol or benzodiazepine withdrawal, which can be fatal.
New Jersey has expanded naloxone (Narcan) access through standing orders, making the overdose-reversal medication available at pharmacies without an individual prescription.
New Jersey has approximately 80 federally certified opioid treatment programs (OTPs) and was among the first states to mandate emergency department-initiated buprenorphine treatment.

The Opioid Crisis in New Jersey

New Jersey has been one of the hardest-hit states in the national opioid epidemic. The crisis evolved in three distinct waves: the first driven by prescription opioid overprescribing in the late 1990s and 2000s, the second by a surge in heroin use as prescription access tightened, and the third — and most deadly — by the proliferation of illicitly manufactured fentanyl beginning around 2013.

According to the Centers for Disease Control and Prevention (CDC), New Jersey’s age-adjusted opioid overdose death rate has consistently exceeded the national average. The NJ Department of Health publishes real-time overdose data through its surveillance dashboard, which tracks suspected overdose deaths by county, substance, and demographic factors.

County-Level Impact

Several New Jersey counties have been disproportionately affected. Camden, Atlantic, Monmouth, Ocean, and Essex counties have recorded some of the highest per-capita overdose death rates in the state. The crisis does not discriminate by geography, age, or socioeconomic status — suburban and rural communities have been affected alongside urban centers.

Atlantic County has consistently ranked among the hardest hit on a per-capita basis, with the NJ Department of Health reporting rates well above the state average. Cape May and Cumberland counties in southern New Jersey have also experienced elevated overdose mortality relative to their populations. In northern New Jersey, Essex County — which includes Newark — has recorded high absolute numbers of overdose deaths, driven in part by population density and concentrated poverty in certain areas.

The geographic distribution of overdose deaths in New Jersey reflects the drug supply chain as much as it reflects population vulnerability. Fentanyl-laced heroin and counterfeit pills enter the state primarily through the I-95 corridor and the Port of Newark-Elizabeth, creating exposure patterns that affect communities near major transportation routes.

State Response Initiatives

New Jersey’s state government has responded with several initiatives, including the establishment of opioid response teams in every county, expanded access to naloxone (Narcan), increased funding for medication-assisted treatment (MAT), and the NJ Harm Reduction Center network. In 2023, the state launched expanded recovery support services through the Division of Mental Health and Addiction Services (DMHAS).

Additional state actions include the NJ Opioid Prescribing Guidelines, which limited initial opioid prescriptions for acute pain to a five-day supply; mandatory prescriber education on opioid risks; and the integration of the NJ Prescription Drug Monitoring Program (NJPMP) into clinical workflows to identify patients receiving opioids from multiple prescribers. The state has also funded syringe service programs and naloxone distribution through county health departments and community organizations.

Understanding Opioid Withdrawal

Opioid withdrawal occurs when a person who has developed physical dependence on opioids reduces or stops use. The experience is often described as an extreme flu combined with severe anxiety and insomnia. While opioid withdrawal is rarely life-threatening in otherwise healthy adults, it is intensely uncomfortable and is one of the primary reasons people return to opioid use.

Opioid dependence vs. opioid addiction: Physical dependence — the body’s adaptation to the presence of an opioid, resulting in withdrawal symptoms upon cessation — is not the same as addiction. A person taking prescribed opioids under medical supervision may develop physical dependence without meeting the criteria for opioid use disorder. Addiction involves compulsive use, loss of control, and continued use despite harm, in addition to physical dependence.

Withdrawal Timeline

The timeline varies depending on whether the opioid is short-acting (heroin, oxycodone, fentanyl) or long-acting (methadone, extended-release morphine).

Short-acting opioids (heroin, oxycodone, immediate-release fentanyl):

6 to 12 hours after last dose: Early symptoms begin — anxiety, muscle aches, sweating, runny nose, yawning, lacrimation (excessive tearing).
24 to 72 hours: Peak symptoms — nausea, vomiting, diarrhea, abdominal cramps, dilated pupils, rapid heartbeat, insomnia, gooseflesh (piloerection). This is the period of greatest discomfort and highest risk of return to use.
5 to 7 days: Acute symptoms gradually subside, though fatigue, irritability, and sleep disturbances may persist.

Long-acting opioids (methadone, extended-release morphine, buprenorphine):

24 to 48 hours after last dose: Onset of symptoms.
72 to 96 hours: Peak intensity.
7 to 14 days: Gradual resolution of acute symptoms.

Post-acute withdrawal syndrome (PAWS): Symptoms including mood instability, low energy, difficulty concentrating, and intermittent cravings can persist for weeks or months after the acute phase. PAWS is a significant contributor to relapse in the first year of recovery. The mechanisms underlying PAWS are not fully understood, but they appear to involve the slow normalization of neurotransmitter systems — particularly dopamine and endorphin pathways — that were disrupted during active opioid use.

For a detailed breakdown, see the guide to opioid withdrawal symptoms and timeline.

The physical symptoms of withdrawal are driven by the body’s adjustment to functioning without the opioid it had adapted to. The sympathetic nervous system, suppressed during opioid use, rebounds — producing the racing heart, sweating, and gastrointestinal symptoms characteristic of withdrawal. The Clinical Opiate Withdrawal Scale (COWS) is the standard clinical tool used to assess withdrawal severity, scoring symptoms on a scale from mild to severe.

Opioid Withdrawal Treatment and Medications

Medical management of opioid withdrawal significantly reduces discomfort and improves the likelihood of completing detoxification and transitioning to ongoing treatment. Withdrawal treatment protocols are guided by the American Society of Addiction Medicine (ASAM) and typically involve one or more of the following:

Buprenorphine (Suboxone, Subutex): A partial opioid agonist that reduces cravings and withdrawal symptoms without producing the euphoria associated with full agonists. Buprenorphine can be initiated during the withdrawal period (typically after symptoms have begun, at a COWS score of 8 or higher) and continued as maintenance treatment. It is available in outpatient settings, making it the most accessible MAT option. Suboxone, the most commonly prescribed formulation, combines buprenorphine with naloxone to deter misuse via injection.

Clonidine (Catapres): An alpha-2 adrenergic agonist that reduces many autonomic symptoms of withdrawal — sweating, anxiety, muscle aches, restlessness — but does not address cravings. Clonidine is often used as an adjunct medication rather than a primary treatment. It can cause hypotension, so blood pressure monitoring is required during use.

Supportive medications: Loperamide (Imodium) for diarrhea, ondansetron (Zofran) for nausea, trazodone or hydroxyzine for insomnia, and ibuprofen or acetaminophen for pain are commonly used to manage specific symptoms.

Methadone taper: In some clinical settings, a short methadone taper is used for medically managed withdrawal. However, abrupt cessation of methadone itself produces a prolonged withdrawal, so this approach requires clinical oversight. Methadone tapers are more commonly used in inpatient or residential settings where daily monitoring is available.

Rapid and ultra-rapid detox protocols: Some facilities advertise rapid detox under sedation, but ASAM and NIDA do not recommend these approaches due to safety concerns. Research published in JAMA found no significant benefit of rapid detox over standard medical withdrawal management, with higher rates of adverse events.

New Jersey has an extensive network of detoxification facilities, including hospital-based programs, freestanding detox centers, and residential treatment programs that incorporate detox services. The state’s NJ 2-1-1 helpline can assist individuals in locating available detox beds. Several NJ hospitals, including Jersey Shore University Medical Center and Hackensack Meridian Health facilities, have implemented emergency department-initiated buprenorphine programs that begin treatment during the ED visit and connect patients with outpatient follow-up.

How Opioid Withdrawal Compares to Other Substances

Not all withdrawal syndromes carry the same level of medical risk. Understanding the differences between withdrawal types is clinically important.

Opioid vs. alcohol withdrawal: Alcohol withdrawal can produce seizures and delirium tremens (DTs), both of which can be fatal without medical intervention. Opioid withdrawal, while extremely uncomfortable, is generally not life-threatening in otherwise healthy individuals. This distinction is critical: the medical urgency of alcohol and benzodiazepine withdrawal is higher than opioid withdrawal, though all three benefit from medical supervision. However, opioid withdrawal can be dangerous for individuals with serious underlying health conditions, and dehydration from vomiting and diarrhea requires management.

Opioid vs. benzodiazepine withdrawal: Benzodiazepine withdrawal shares the seizure risk of alcohol withdrawal and typically requires a slow, medically supervised taper over weeks or months. Opioid withdrawal does not carry seizure risk under normal circumstances. The duration of benzodiazepine withdrawal is often significantly longer than opioid withdrawal.

Opioid vs. stimulant withdrawal: Stimulant withdrawal (cocaine, methamphetamine) is primarily psychological — depression, fatigue, anhedonia, hypersomnia — rather than the physically intense syndrome seen with opioids. There is no established medication protocol for stimulant withdrawal comparable to MAT for opioids.

Fentanyl: The Driving Force Behind NJ Overdose Deaths

Illicitly manufactured fentanyl has fundamentally changed the overdose landscape in New Jersey and nationally. Fentanyl is a synthetic opioid estimated to be 50 to 100 times more potent than morphine, according to the CDC. It is increasingly found not only in heroin but pressed into counterfeit pills designed to resemble legitimate pharmaceuticals (including fake oxycodone, Xanax, and Adderall) and mixed into stimulants such as cocaine and methamphetamine, meaning individuals who do not intend to use opioids may be exposed.

Illicit Manufacturing and Distribution

Unlike heroin, which is derived from the opium poppy plant, fentanyl is entirely synthetic and can be manufactured in clandestine laboratories without agricultural inputs. The precursor chemicals are primarily sourced from chemical suppliers in China and other countries, then synthesized into fentanyl and fentanyl analogs (such as carfentanil, which is approximately 100 times more potent than fentanyl itself) in laboratories operated by transnational drug trafficking organizations. The DEA has identified Mexico-based cartels as the primary source of illicitly manufactured fentanyl entering the United States.

The economics of illicit fentanyl favor its proliferation: it is cheaper to produce than heroin, more potent by weight (meaning smaller quantities generate higher profits), and does not depend on seasonal crop yields. This economic reality makes it unlikely that fentanyl will disappear from the drug supply, which is why harm reduction strategies — including fentanyl test strips and widespread naloxone distribution — have become a critical component of public health response.

Fentanyl Test Strips

Fentanyl test strips allow individuals to test substances for the presence of fentanyl before use. New Jersey legalized the possession and distribution of fentanyl test strips in 2022, removing them from the state’s drug paraphernalia definition. Test strips are available through harm reduction organizations, syringe service programs, and some pharmacies in New Jersey. While test strips cannot determine the potency of fentanyl present, they provide a binary result — fentanyl detected or not detected — that can inform decisions about use.

Treatment Challenges Specific to Fentanyl

The New Jersey Department of Health reports that fentanyl is now present in the majority of overdose deaths statewide. The drug’s potency means that the margin between a dose that produces the desired effect and a dose that causes respiratory arrest is extremely narrow.

Fentanyl addiction presents specific treatment challenges. Individuals with fentanyl dependence may require higher doses of buprenorphine to manage withdrawal symptoms, and the induction process — the period when buprenorphine is first administered — may need to be modified. Traditional buprenorphine induction requires waiting until the patient is in moderate withdrawal (to avoid precipitated withdrawal), but fentanyl’s long tissue half-life means it can remain in the body longer than expected, complicating this timing. Some clinicians use micro-dosing (also called micro-induction or the Bernese method) protocols to initiate buprenorphine in patients with fentanyl dependence, gradually introducing buprenorphine while the patient continues to have fentanyl in their system.

For a clinical comparison of potency and pharmacology, see fentanyl vs. morphine. For accounts of what the recovery process looks like for individuals who developed fentanyl dependence, see fentanyl recovery narratives.

Treatment Options for Opioid Addiction

Opioid addiction is treatable. The most effective approaches combine medication with behavioral therapy and psychosocial support. NIDA identifies medication-assisted treatment (MAT) as the gold standard for opioid use disorder, associated with reduced opioid use, decreased overdose deaths, improved treatment retention, and better social functioning.

Medication-Assisted Treatment (MAT)

Three FDA-approved medications are used to treat opioid use disorder:

Buprenorphine (Suboxone, Subutex, Sublocade, Zubsolv): A partial opioid agonist that occupies opioid receptors, reducing cravings and withdrawal without producing significant euphoria at prescribed doses. Available as a sublingual film (Suboxone), sublingual tablet (Subutex, Zubsolv), or monthly subcutaneous injection (Sublocade). Can be prescribed by any clinician with a DEA registration — the federal X-waiver requirement was eliminated in 2023 under the Mainstreaming Addiction Treatment (MAT) Act, significantly expanding access. In New Jersey, buprenorphine can be prescribed in primary care offices, emergency departments, and specialized addiction treatment programs.

Methadone (Dolophine, Methadose): A full opioid agonist dispensed through federally regulated opioid treatment programs (OTPs). Methadone is taken daily under supervision (initially), with take-home privileges earned over time based on demonstrated stability and adherence. New Jersey has approximately 80 OTP locations across the state. Methadone is the oldest and most extensively studied medication for opioid use disorder, with research spanning more than 50 years demonstrating its effectiveness in reducing illicit opioid use, criminal activity, and overdose mortality.

Naltrexone (ReVia, Vivitrol): An opioid antagonist that blocks the effects of opioids entirely. Available as a daily oral tablet (ReVia) or a monthly intramuscular injection (Vivitrol). Requires the patient to be fully detoxified from opioids before initiation — typically 7 to 10 days opioid-free — which can be a barrier for some individuals. Vivitrol eliminates the adherence challenge of daily dosing, as one injection provides 30 days of opioid blockade.

Despite the strong evidence for MAT, treatment access remains uneven. SAMHSA data indicate that only approximately 18 percent of individuals with opioid use disorder nationally receive medication treatment. In New Jersey, the state has worked to expand MAT access through Medicaid coverage requirements, emergency department initiation programs, and the integration of buprenorphine prescribing into primary care settings.

For a deeper exploration of how these medications work and what to expect, see the guide to Suboxone treatment and the broader medication-assisted treatment overview.

Heroin and Prescription Opioid Treatment Differences

While heroin addiction and prescription painkiller addiction are both opioid use disorders, they may differ in treatment context. Individuals with prescription opioid dependence sometimes transition to heroin or fentanyl when prescription access is cut off — a pattern that has been well-documented in epidemiological research. A study published in JAMA Psychiatry found that approximately 80 percent of people who initiated heroin use in recent years had previously misused prescription opioids. Treatment approaches are largely the same (MAT, behavioral therapy, psychosocial support), though the entry point, stigma, and co-occurring issues may differ.

Behavioral Therapies

Medication addresses the physiological component of opioid addiction, but behavioral therapies address the cognitive, emotional, and social dimensions. Common evidence-based approaches include:

Cognitive-behavioral therapy (CBT): Identifies and restructures thought patterns associated with substance use. CBT helps individuals develop coping strategies for triggers and high-risk situations.
Contingency management: Uses tangible incentives to reinforce positive behaviors such as attending treatment and producing negative drug screens. Research reviewed by NIDA shows contingency management is among the most effective behavioral approaches for substance use disorders.
Motivational interviewing (MI): A collaborative counseling approach that strengthens a person’s own motivation for change. MI is particularly useful for individuals who are ambivalent about entering or continuing treatment.
Twelve-step facilitation: A structured approach to engaging patients with AA, NA, or other mutual aid groups as a complement to clinical treatment.

Special Considerations: Pregnancy and Kratom

Opioid Use During Pregnancy

Opioid withdrawal during pregnancy poses specific risks. Abrupt withdrawal can cause uterine contractions and fetal distress, and is associated with increased risk of miscarriage (in early pregnancy) and preterm labor (in later pregnancy). For this reason, ACOG (the American College of Obstetricians and Gynecologists) and SAMHSA recommend that pregnant individuals with opioid use disorder be treated with medication — specifically buprenorphine or methadone — rather than undergoing medically managed withdrawal.

Neonatal abstinence syndrome (NAS), a condition in which a newborn experiences withdrawal symptoms after in-utero opioid exposure, is a known outcome of MAT during pregnancy. However, the risks of untreated opioid use disorder during pregnancy — including overdose, preterm birth, and placental abruption — are considered significantly greater than the risks associated with NAS, which is treatable. NAS typically manifests within 48 to 72 hours of birth and is managed through supportive care, with pharmacological intervention (typically morphine or methadone) used in more severe cases.

In New Jersey, several hospitals have specialized programs for pregnant individuals with opioid use disorder, including programs that coordinate obstetric care with addiction medicine. NJ Medicaid covers both buprenorphine and methadone treatment during pregnancy and postpartum.

Kratom and Opioids

Kratom (Mitragyna speciosa) is a plant-derived substance that acts on opioid receptors and is sometimes used for self-managed opioid withdrawal. The FDA has not approved kratom for any medical use and has issued warnings about its safety profile. The evidence for kratom as an opioid withdrawal aid is limited and largely anecdotal. Kratom itself carries risks of dependence, and contaminated products have been linked to salmonella outbreaks and heavy metal exposure. The American Kratom Association has advocated for regulation rather than prohibition, but major medical organizations including ASAM and the AMA have called for more research before endorsing any clinical use.

NJ Opioid Resources and Data

New Jersey maintains several resources specifically for individuals affected by opioid addiction:

NJ Department of Health Overdose Dashboard — Real-time suspected overdose death data by county and substance. Publicly accessible at the NJ DOH website.
NJ 2-1-1 — A statewide helpline that connects individuals to addiction treatment, mental health services, and social services. Available 24/7 by dialing 2-1-1.
ReachNJ — A 24/7 peer recovery support line staffed by individuals with lived experience in recovery. Available by calling 1-844-ReachNJ (1-844-732-2465).
Naloxone (Narcan) access — New Jersey has a standing order that allows any person to obtain naloxone (Narcan) from a pharmacy without an individual prescription. Many NJ counties also distribute free naloxone through local health departments and community organizations. Narcan nasal spray became available over-the-counter nationally in 2023.
NJ Opioid Treatment Programs (OTPs) — The state has approximately 80 federally certified OTPs offering methadone and buprenorphine treatment. A directory is maintained by SAMHSA’s treatment locator at findtreatment.gov.
NJ Harm Reduction Centers — Community-based organizations offering syringe services, naloxone distribution, fentanyl test strips, wound care, and linkage to treatment. Locations operate in several NJ counties.
NJPMP (NJ Prescription Monitoring Program) — A database that tracks controlled substance prescriptions to identify potential misuse. Accessible to prescribers and pharmacists.

For a broader view of state-specific treatment resources, insurance assistance, and recovery support services, see the NJ resources guide. For definitions of clinical terminology used in this guide, see the glossary.

For information on how opioid treatment fits within the broader landscape of addiction care, see the complete guide to types of addiction treatment.

Topics in This Guide

The Opioid Crisis in New Jersey
Understanding Opioid Withdrawal
Opioid Withdrawal Treatment and Medications
How Opioid Withdrawal Compares to Other Substances
Fentanyl: The Driving Force Behind NJ Overdose Deaths
Treatment Options for Opioid Addiction
Special Considerations: Pregnancy and Kratom
NJ Opioid Resources and Data

Looking for treatment options in your area? We can help point you in the right direction. (800) 555-0199 — or request a callback.